The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
2001
Enhancing Cisplatin's Effect with AQ4N
publication
Evidence: moderate
Author Information
Author(s): Gallagher R, Hughes C M, Murray M M, Friery O P, Patterson L H, Hirst D G, McKeown S R
Primary Institution: Radiation Science Research Group, School of Biomedical Sciences, University of Ulster at Jordanstown
Hypothesis
Can AQ4N enhance the anti-tumour effect of cisplatin compared to tirapazamine?
Conclusion
AQ4N has the potential to improve the clinical efficacy of cisplatin.
Supporting Evidence
- AQ4N enhanced the anti-tumour effect of cisplatin by 1.5 to 2 times.
- Tirapazamine provided only a small increase in anti-tumour efficacy compared to AQ4N.
- AQ4N resulted in greater cell kill than tirapazamine in murine tumour models.
- Combining AQ4N with cisplatin did not increase bone marrow toxicity.
Takeaway
AQ4N is a drug that helps make another cancer drug, cisplatin, work better without causing more side effects.
Methodology
AQ4N was administered in a murine tumour model before cisplatin to assess its effect on anti-tumour efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website